The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit theSCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
Bd. Smolich et al., The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit theSCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts, BLOOD, 97(5), 2001, pp. 1413-1421
SU5416 and SU6668 are potent antiangiogenic small-molecule inhibitors of re
ceptor tyrosine kinases, including those of the vascular endothelial growth
factor and platelet-derived growth factor receptor families. The stem cell
factor (SCF) receptor, c-kit, is structurally related to these receptors a
nd, although not expressed on mature peripheral blood cells, is expressed i
n leukemic blasts derived from 60% to 80% of acute myeloid leukemia (AML) p
atients. The c-kit kinase inhibitory activity of SU5416 and SU6668 was eval
uated in MO7E cells, a human myeloid leukemia cell line. Tyrosine autophosp
horylation of the receptor, induced by SCF, was inhibited in these cells by
SU5416 and SU6668 in a dose-dependent manner (inhibitory concentration of
50% [IC50] 01.1 muM). Inhibition of extracellular signal-regulated kinase 1
/2 (ERK1/2) phosphorylation, a signaling event down-stream of c-kit activat
ion, was also inhibited in a dose-dependent manner. Both compounds also inh
ibited SCF-induced proliferation of MO7E cells (IC50 0.1 muM for SU5416; 0.
29 muM for SU6668). Furthermore, both SU5416 and SU6668 induced apoptosis i
n a dose- and time-dependent manner as measured by the increase in activate
d caspase-3 and the enhanced cleavage of its substrate poly(ADP-ribose) pol
ymerase. These findings with MO7E cells were extended to leukemic blasts fr
om c-kit(+) patients. In patient blasts, both SU5416 and SU6668 inhibited S
CF-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. These
studies indicate that SU5416 and SU6668 inhibit biologic functions of c-ki
t in addition to exhibiting antiangiogenic properties and suggest that the
combination of these activities may provide a novel therapeutic approach fo
r the treatment of AML. (Blood, 2001;97:1413-1421) (C) 2001 by The American
Society of Hematology.